These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 27171036)

  • 1. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
    Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
    J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy.
    Mallareddy JR; Singh S; Boghean L; Natarajan A
    Future Med Chem; 2022 Jan; 14(3):131-134. PubMed ID: 34814708
    [No Abstract]   [Full Text] [Related]  

  • 3. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
    Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
    Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK9 a potential target for drug development.
    Canduri F; Perez PC; Caceres RA; de Azevedo WF
    Med Chem; 2008 May; 4(3):210-8. PubMed ID: 18473913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
    Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
    Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
    Hole AJ; Baumli S; Shao H; Shi S; Huang S; Pepper C; Fischer PM; Wang S; Endicott JA; Noble ME
    J Med Chem; 2013 Feb; 56(3):660-70. PubMed ID: 23252711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
    King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
    Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
    Alsfouk A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations.
    Singh P; Kumar V; Jung TS; Lee JS; Lee KW; Hong JC
    J Mol Model; 2024 Jul; 30(8):267. PubMed ID: 39012568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
    Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
    J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
    Jing L; Tang Y; Xiao Z
    Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
    Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
    Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
    Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
    Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
    Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
    Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
    J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel, selective CDK9 inhibitors for the treatment of HIV infection.
    Németh G; Varga Z; Greff Z; Bencze G; Sipos A; Szántai-Kis C; Baska F; Gyuris A; Kelemenics K; Szathmáry Z; Minárovits J; Kéri G; Orfi L
    Curr Med Chem; 2011; 18(3):342-58. PubMed ID: 21143121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
    Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
    PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
    Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
    Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.
    Baumli S; Hole AJ; Noble ME; Endicott JA
    ACS Chem Biol; 2012 May; 7(5):811-6. PubMed ID: 22292676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological targeting of CDK9 in cardiac hypertrophy.
    Krystof V; Chamrád I; Jorda R; Kohoutek J
    Med Res Rev; 2010 Jul; 30(4):646-66. PubMed ID: 19757441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.